Search

Displaying results 7581 - 7590 of 10000 in total
  1. Drug

    Hexestrol

    go.drugbank.com/drugs/DB07931
    ApprovedWithdrawn

    A synthetic estrogen that has been used as a hormonal antineoplastic agent.

    Synonyms: Meso-3,4-di(p-hydroxyphenyl)-n-hexane
  2. Drug

    AeroLEF

    go.drugbank.com/drugs/DB05000
    Investigational

    AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia … AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain.

  3. Drug

    NCX 701

    go.drugbank.com/drugs/DB05409
    Experimental

    Nitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.

  4. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

  5. Drug

    Moxestrol

    go.drugbank.com/drugs/DB13418
    Experimental

    Categories: Sex Hormones and Modulators of the Genital System
  6. Drug

    Cyclohexanone

    go.drugbank.com/drugs/DB02060
    Experimental

    Cyclohexanone (also known as oxocyclohexane, pimelic ketone, ketohexamethylene, cyclohexyl ketone or ketocyclohexane) is a six-carbon cyclic molecule with a ketone functional group. … It is a colorless, oily liquid with an acetone-like smell.

  7. Drug

    Tesevatinib

    go.drugbank.com/drugs/DB11973
    Investigational

    Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. … In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression.

  8. Drug

    SC-236

    go.drugbank.com/drugs/DB14059
    Experimental

    SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and inflammation [A33373], [A33374

  9. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

  10. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210). … MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein.